Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | PEPD | P12955 | 1/20 | 0.31 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22360773 | 1.00 | ATM (0.38) | ATMDPP4DPP8DPP9ACE | |
| SCHEMBL17995266 | 1.00 | ATM (0.38) | ATMDPP4DPP8DPP9ACE | |
| SCHEMBL19540491 | 1.00 | ATM (0.38) | ATMDPP4DPP8DPP9ACE | |
| Hydrochloric Acid SCHEMBL1493679 | 0.98 | ATM (0.37) | ATMDPP4DPP8DPP9ACE | |
| SCHEMBL17641844 | 0.83 | PIN1 (0.33) | ATMDPP4DPP8DPP9PIN1 | |
| SCHEMBL21515921 | 0.83 | PIN1 (0.33) | ATMDPP4DPP8DPP9PIN1 | |
| SCHEMBL13165479 | 0.83 | PIN1 (0.33) | ATMDPP4DPP8DPP9PIN1 | |
| SCHEMBL8915827 | 0.83 | PIN1 (0.33) | ATMDPP4DPP8DPP9PIN1 | |
| SCHEMBL10140519 | 0.81 | DPP4 (0.31) | DPP4DPP8DPP9PIN1PEPD | |
| SCHEMBL12861032 | 0.81 | PIN1 (0.41) | DPP4DPP8DPP9PIN1PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250042843-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2805726-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2008144380-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021928-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | ATM 4646/4885DPP4 1532/4885DPP8 1575/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ATM 3538/4885DPP4 379/4885DPP8 109/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | ATM 1781/4885DPP4 19/4885DPP8 342/4885 |
| US-20250042843-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | ATM 4646/4885DPP4 1532/4885DPP8 1575/4885 |
| US-20260109665-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | CBR1, CYP7A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ATM 4498/4885DPP4 3651/4885DPP8 3206/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ATM 3538/4885DPP4 379/4885DPP8 109/4885 |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | ATM 4646/4885DPP4 1532/4885DPP8 1575/4885 |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | ATM 4646/4885DPP4 1532/4885DPP8 1575/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885DPP4 2492/4885DPP8 929/4885 |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | PDGFRA, PDGFRB, ABL1 | ATM 838/4885DPP4 858/4885DPP8 827/4885 |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ATM 3538/4885DPP4 379/4885DPP8 109/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | ATM 2907/4885DPP4 2754/4885DPP8 2092/4885 |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | ATM 4646/4885DPP4 1532/4885DPP8 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.